These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33349572)

  • 1. Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
    Davis A; Mahar A; Wong K; Barnet M; Kao S
    Clin Lung Cancer; 2021 Sep; 22(5):e665-e667. PubMed ID: 33349572
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab in non-small-cell lung cancer with EGFR mutation.
    Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Funazo T; Hirai T
    Ann Oncol; 2018 Mar; 29(3):777-778. PubMed ID: 29161357
    [No Abstract]   [Full Text] [Related]  

  • 3. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.
    Roesel C; Kambartel K; Kopeika U; Berzins A; Voshaar T; Krbek T
    Curr Oncol; 2019 Apr; 26(2):e270-e273. PubMed ID: 31043837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative Nivolumab in Resectable Lung Cancer.
    Sorscher S
    N Engl J Med; 2024 Aug; 391(6):573. PubMed ID: 39115073
    [No Abstract]   [Full Text] [Related]  

  • 5. Perioperative Nivolumab in Resectable Lung Cancer. Reply.
    Cascone T; Spicer JD; Provencio Pulla M
    N Engl J Med; 2024 Aug; 391(6):573-574. PubMed ID: 39115074
    [No Abstract]   [Full Text] [Related]  

  • 6. Nivolumab improves survival for patients with advanced lung cancer.
    Printz C
    Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
    [No Abstract]   [Full Text] [Related]  

  • 7. Perioperative Nivolumab in Resectable Lung Cancer.
    Sobrero S; Vaisitti F; Leo F
    N Engl J Med; 2024 Aug; 391(6):572-573. PubMed ID: 39115072
    [No Abstract]   [Full Text] [Related]  

  • 8. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
    Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
    [No Abstract]   [Full Text] [Related]  

  • 9. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
    Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.
    Kimura H; Araya T; Yoneda T; Shirasaki H; Kurokawa K; Sakai T; Koba H; Tambo Y; Nishikawa S; Sone T; Kasahara K
    Cancer Commun (Lond); 2019 Nov; 39(1):78. PubMed ID: 31753015
    [No Abstract]   [Full Text] [Related]  

  • 11. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    Funazo T; Nomizo T; Kim YH
    J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy for non-small cell lung cancer.
    Vafadar S
    JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
    Guihot A; Marcelin AG; Massiani MA; Samri A; Soulié C; Autran B; Spano JP
    Ann Oncol; 2018 Feb; 29(2):517-518. PubMed ID: 29206889
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Giaj Levra M; Cotté FE; Corre R; Calvet C; Gaudin AF; Penrod JR; Grumberg V; Jouaneton B; Jolivel R; Assié JB; Chouaïd C
    Lung Cancer; 2020 Feb; 140():99-106. PubMed ID: 31911324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
    Bott MJ; Yang SC; Park BJ; Adusumilli PS; Rusch VW; Isbell JM; Downey RJ; Brahmer JR; Battafarano R; Bush E; Chaft J; Forde PM; Jones DR; Broderick SR
    J Thorac Cardiovasc Surg; 2019 Jul; 158(1):269-276. PubMed ID: 30718052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
    Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
    Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
    Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice.
    Merino Almazán M; Duarte Pérez JM; Marín Pozo JF; Ortega Granados AL; Muros De Fuentes B; Quesada Sanz P; Gago Sánchez AI; Rodríguez Gómez P; Jurado García JM; Artime Rodríguez-Hermida F; Martínez Bautista MJ; Rueda Ramos A; Mora Rodríguez B; Martínez Díaz MC; Nieto Guindo P; Garrido Siles M; Villatoro Roldán R; Roldán Morales JC; Artacho Criado SM; Baños Roldán Ú; Inoriza Rueda Á; Garrido Martínez MT
    Int J Clin Pharm; 2019 Feb; 41(1):272-279. PubMed ID: 30578473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
    Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
    Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.